Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025
상품코드:1810901
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.5%로 24억 9,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장의 원동력은 저침습적 치료 옵션에 대한 선호도 증가, 여성 건강 문제에 대한 인식 증가, 병용 요법의 가용성 확대, 개발도상국의 의료 접근성 개선, 신규 제제 파이프라인 증가 등입니다. 이번 분기에는 경구용 GnRH 길항제 제제의 발전, 호르몬제 애드백을 특징으로 하는 병용요법의 혁신, 생식 치료 모니터링을 위한 디지털 헬스 기술 도입, 승인 가속화를 위한 임상시험 설계의 발전, 호르몬 요법에서 원격의료 활용 확대 등이 주요 동향으로 꼽힙니다. 확대 등이 있습니다.
난소암과 전립선암의 발병률 증가는 향후 성선자극호르몬 방출 호르몬(GnRH) 작용제 및 길항제 시장의 성장을 촉진할 것으로 예측됩니다. 난소암과 전립선암은 에스트로겐과 테스토스테론의 영향을 받는 호르몬 민감성 종양으로, GnRH 작용제나 길항제와 같은 호르몬 조절 요법으로 치료하는 경우가 많습니다. 난소암과 전립선암 환자 수 증가는 평균 수명 연장과 관련이 있는데, 이는 호르몬 민감성 암의 발병 위험이 나이가 들면서 증가하기 때문입니다. GnRH 작용제 및 길항제는 이러한 종양의 성장을 가속하는 에스트로겐, 테스토스테론과 같은 성호르몬의 생성을 억제함으로써 난소암과 전립선암 치료에 도움이 됩니다. 예를 들어 정부 기관인 Cancer Australia는 2023년 호주에서 약 1,786명의 난소암 환자가 새로 진단될 것으로 예상하고 있습니다. 또한 여성이 85세까지 난소암 진단을 받을 확률은 약 87분의 1(또는 1.2%)입니다. 이처럼 난소암과 전립선암의 유병률 증가가 GnRH 작용제 및 길항제 시장의 성장을 촉진하고 있습니다.
성선자극호르몬 방출 호르몬(GnRH) 작용제 및 길항제 시장의 주요 업체들은 경구용 GnRH 수용체 길항제와 같은 혁신적인 치료법을 개발하여 환자의 편의성을 높이고 치료 순응도를 높이며 주사 요법에 대한 의존도를 낮추기 위해 노력하고 있습니다. 경구용 GnRH 수용체 길항제는 GnRH 수용체를 차단해 성호르몬 수치를 빠르게 낮추는 약으로 전립선암, 자궁내막증 등 호르몬 관련 질환 치료에 도움이 됩니다. 예를 들어 2024년 3월 스미토모제약은 전립선암이나 자궁내막증과 같은 호르몬 관련 질환의 치료에 도움이 되는 GnRH 수용체 길항제를 개발했습니다. 일본에 본사를 둔 제약회사 스미토모제약은 진행성 전립선암에 대한 최초이자 유일한 경구용 안드로겐 제거 요법(ADT)인 오르가빅스(성분명: 레고릭스)가 캐나다 보건부로부터 승인을 받아 현재 캐나다에서 판매되고 있다고 발표했습니다. ORGOVYX는 1일 1회 경구용 GnRH 수용체 길항제로 전립선암 진행의 주요 원인인 테스토스테론 생성을 억제합니다. ORGOVYX의 승인은 3상 HERO 임상을 기반으로 하며, 표준 주사 치료와 비교하여 효과적이고 지속적인 테스토스테론 억제, 주요 심혈관계 사건 감소, 동등한 수준의 무거세 저항성 생존율을 보였습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 성장률 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 실적 : 규모와 성장, 2019-2024
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 약제 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
GnRH 아고니스트
Leuprorelin
Goserelin
Triptorelin
Histrelin
Buserelin
GnRH Antagonists
Degarelix
Abarelix
기타 약제 유형
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
부인과
종양학
기타 용도
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
기타 최종사용자
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, GnRH 아고니스트(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Deslorelin
Gonadorelin
Zoladex Long-Acting Goserelin Variant
Lupron Depot-Ped
서방형 마이크로스피어 제제
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Leuprorelin(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
데포 주사
임플란트
병용요법 제제
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Goserelin(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
피하 임플란트
종양학 특이성 제제
부인과 전용 처방
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Triptorelin(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
근육내 주사
장기 작용형(1, 3, 6개월) 데포제
불임 치료 처방
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Histrelin, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
피하 임플란트
소아용(성조숙증) 제제
성인 전립선암 특이 버전
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Buserelin(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
비강 스프레이
피하 주사
체외수정 및 임신 주기 제제
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, GnRH 길항제(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Teverelix DP
Elagolix
Relugolix
Ganirelix
Linzagolix
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Degarelix, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
피하 주사
월 1회 투여
전립선암 특이성 제제
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, Abarelix, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
근육내 주사
진행성 전립선암
단시간 작용형 제제
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 서브 세분화, 기타 약제 유형, 실적과 예측, 2019-2024, 2024-2029F, 2034F
피하 주사
체외수정 특유 용도
다중 투여 레지멘
제7장 지역별·국가별 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 경쟁 구도
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Intas Pharmaceuticals Limited
Sumitomo Pharma Co. Ltd.
Ipsen S.A.
Dr. Reddy's Laboratories Limited
Cipla Limited
Gedeon Richter Plc
Lupin Limited
Zydus Lifesciences Limited
Gland Pharma Limited
Bachem Holding AG
Kissei Pharmaceutical Co. Ltd.
Aska Pharmaceutical Co. Ltd.
Ferring International Center S.A.
Tolmar Inc.
Debiopharm International SA
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 2029 : 새로운 기회를 제공하는 국가
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 2029 : 새로운 기회를 제공하는 부문
고나도트로핀 방출 호르몬(GnRH) 작용제 및 길항제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Gonadotropin-releasing hormone (GnRH) agonists and antagonists are synthetic drugs that control the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. GnRH agonists initially cause an increase in LH and FSH release but eventually lead to their suppression over time. In contrast, GnRH antagonists block GnRH receptors directly, resulting in an immediate reduction of hormone levels.
The primary types of gonadotropin-releasing hormone (GnRH) agonists and antagonists include GnRH agonists such as leuprorelin, goserelin, triptorelin, histrelin, and buserelin, as well as GnRH antagonists like degarelix and abarelix, among others. GnRH agonists mimic the natural hormone GnRH, triggering an initial release of LH and FSH from the pituitary gland, followed by hormone suppression with continued use, thereby reducing sex hormone production. These drugs are used in various fields, including gynecology and oncology, with key end users being hospitals, specialty clinics, and similar healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market statistics, including the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs industry's global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market share, detailed gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market. This gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size has grown strongly in recent years. It will grow from $1.57 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period was driven by a rising prevalence of hormone-related disorders, an increase in prostate and breast cancer cases, heightened awareness of reproductive health, growing demand for assisted reproductive technologies, and greater use of hormone therapies for conditions like endometriosis and uterine fibroids.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth during the forecast period is driven by a growing preference for minimally invasive treatment options, increased awareness of women's health concerns, expanded availability of combination therapies, improved healthcare access in developing regions, and a rising pipeline of novel drug formulations. Key trends expected to shape this period include progress in oral GnRH antagonist formulations, innovations in combination therapies featuring hormonal add-back, incorporation of digital health technologies for monitoring reproductive treatments, advancements in clinical trial designs to accelerate approvals, and the growing use of telemedicine in hormone therapy.
The rising incidence of ovarian and prostate cancers is expected to drive the growth of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in the future. Ovarian and prostate cancers are hormone-sensitive tumors influenced by estrogen and testosterone and are frequently treated with hormone-regulating therapies such as GnRH agonists or antagonists. The increase in ovarian and prostate cancer cases is linked to longer life expectancy, as the risk of developing these hormone-sensitive cancers rises with age. GnRH agonists and antagonists help treat ovarian and prostate cancers by suppressing the production of sex hormones like estrogen and testosterone, which promote the growth of these tumors. For example, in 2023, Cancer Australia, a government agency, reported that around 1,786 new ovarian cancer cases are expected to be diagnosed in Australia. Additionally, women face approximately a 1 in 87 chance (or 1.2% risk) of being diagnosed with ovarian cancer by age 85. Thus, the increasing prevalence of ovarian and prostate cancers is fueling the growth of the GnRH agonists and antagonists drugs market.
Key players in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market are focusing on developing innovative treatments, such as oral GnRH receptor antagonists, to improve patient convenience, boost treatment adherence, and reduce reliance on injectable therapies. Oral GnRH receptor antagonists are pills that block GnRH receptors to rapidly decrease sex hormone levels, aiding in the treatment of hormone-related conditions like prostate cancer and endometriosis. For instance, in March 2024, Sumitomo Pharma Co. Ltd., a pharmaceutical company based in Japan, announced that ORGOVYX (relugolix), the first and only oral androgen deprivation therapy (ADT) for advanced prostate cancer, received approval from Health Canada and is now available in Canada. ORGOVYX is a once-daily oral GnRH receptor antagonist that suppresses testosterone production, a major factor in prostate cancer progression. Its approval was based on the Phase 3 HERO study, which showed effective and sustained testosterone suppression, a decrease in major cardiovascular events, and similar castration resistance-free survival compared to standard injectable treatments.
In February 2022, Debiopharm Group, a Switzerland-based biopharmaceutical company, partnered with Aspen Pharmacare Holdings Limited to improve treatment options for locally advanced and metastatic hormone-dependent prostate cancer. The collaboration aims to expand access to Debiopharm's GnRH drug, Trelstar, in South Africa, offering effective hormone therapy to patients with advanced prostate cancer by reducing testosterone levels and slowing disease progression. Aspen Pharmacare Holdings Limited is a South Africa-based manufacturer of gonadotropin-releasing hormone (GnRH) agonists.
Major players in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market are Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy's Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, and TiumBio Co. Ltd.
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs market consists of sales of injectable formulations, intranasal spray, subcutaneous implants, microsphere-based depot formulations, and ready-to-use prefilled syringes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: GnRH Agonists; Leuprorelin; Goserelin; Triptorelin; Histrelin; Buserelin; GnRH Antagonists; Degarelix; Abarelix; Other Drug Types
2) By Application: Gynecology; Oncology; Other Applications
3) By End-User: Hospitals; Specialty Clinics; Other End-Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Characteristics
3. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth Rate Analysis
5.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Total Addressable Market (TAM)
6. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Segmentation
6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
GnRH Agonists
Leuprorelin
Goserelin
Triptorelin
Histrelin
Buserelin
GnRH Antagonists
Degarelix
Abarelix
Other Drug Types
6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gynecology
Oncology
Other Applications
6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Deslorelin
Gonadorelin
Zoladex Long-Acting Goserelin Variant
Lupron Depot-Ped
Sustained-Release Microsphere Formulations
6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Depot Injection
Implant
Combination Therapy Formulations
6.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Implant
Oncology-Specific Formulation
Gynecology-Specific Formulation
6.7. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intramuscular Injection
Long-Acting (1-, 3-, 6-Month) Depot
Fertility Treatment Formulation
6.8. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Implant
Pediatric (Precocious Puberty) Formulation
Adult Prostate Cancer-Specific Version
6.9. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Buserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nasal Spray
Subcutaneous Injection
In Vitro Fertilization And Fertility Cycle Formulations
6.10. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Teverelix DP
Elagolix
Relugolix
Ganirelix
Linzagolix
6.11. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Degarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Injection
Monthly Dosing
Prostate Cancer-Specific Formulation
6.12. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Abarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intramuscular Injection
Advanced Prostate Cancer
Short-Acting Formulation
6.13. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Injection
In Vitro Fertilization-Specific Use
Multiple Dosing Regimens
7. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Regional And Country Analysis
7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
19.1. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Landscape And Company Profiles
